Use of Mesenchymal Stem Cells in Inflammatory Bowel Disease

Summary

Scientists hypothesize that directly or parentally injecting Mesenchymal stem cells (MSCs) to affected areas will have a positive impact through reducing or abolishing intestinal inflammation in part via inhibition of neutrophil Myeloperoxidase (MPOx) activity. Inhibiting MPOx should modify disease progression as well as reduce colitis associated cancer risk.

Timeline

Start

2017-06-05

Primary completion

2019-11

Completion

2020-01

Drugs

Indications